Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AB122 plus TAS-120 for previously treated cancer of unknown primary
jRCT2051260023Phase 2Recruiting
- Sponsor
- NA
- Start
- May 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zimberelimab and futibatinib in cancer of unknown primary (CUP), sponsored by NA. Primary endpoint: Objective response rate by independent review. Started May 2026; status: recruiting.
02
Drugs
zimberelimabfutibatinib
03
Conditions
cancer of unknown primary (CUP)
Beyond the preview
Go deeper on jRCT2051260023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051260023.